Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer.
Acta Pharm Sin B
; 12(2): 692-707, 2022 Feb.
Article
en En
| MEDLINE
| ID: mdl-35256940
ADT, androgen deprivation therapy; Anti-PD-1 therapy; CRPC, castration-resistant prostate cancer; Castration-resistant prostate cancer; DMSO, dimethyl sulfoxide; ELISA, enzyme-linked immunosorbent assay; FBS, fetal bovine serum; Fer-1, ferrostatin-1; Ferroptosis; GSH, glutathione; HnRNP L; HnRNP L, heterogeneous nuclear ribonucleoprotein L; IL, interleukin; INF-γ, interferon gamma; Immune checkpoint blockade; Immune escape; PD-1, programmed cell death protein 1; PD-L1; PD-L1, programmed death ligand1; ROS, reactive oxygen species; STAT, signal transducer and activator of transcription; YY1; qRT-PCR, quantitative reverse transcription polymerase chain reaction
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Acta Pharm Sin B
Año:
2022
Tipo del documento:
Article
País de afiliación:
China